HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
about
ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerComparison of tagging single-nucleotide polymorphism methods in association analysesSNP-RFLPing 2: an updated and integrated PCR-RFLP tool for SNP genotyping.EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells.In search of breast cancer culprits: suspecting the suspected and the unsuspectedOvarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.Copy number increase of HER-2 in colorectal cancers.A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.Genomic organization and control of the grb7 gene family.Heritable variation of ERBB2 and breast cancer risk.MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamicsCyclin K goes with Cdk12 and Cdk13Overexpression of STARD3 in human monocyte/macrophages induces an anti-atherogenic lipid phenotypeThe cyclin K/Cdk12 complex: an emerging new player in the maintenance of genome stability.Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects.HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.Focus on ERBB2.
P2860
Q24810389-6ED312E6-E369-4974-B24D-4D22CC7344AAQ33333026-DD20DBA6-A744-49F7-B48B-0E3110DC939CQ33551006-ADE2D82E-DD1F-4A50-B493-2AD75EEDE66CQ34121550-845A2408-155B-4937-A807-A52C384FF724Q35015572-B0C80A11-3D21-41BD-80AC-98BE02FCC9F0Q35171578-4C92373D-82E8-4952-99D0-5BAE34140EA3Q36135873-EA068986-1D31-4986-A56F-8AB6ECF2883EQ36234011-8F4E3D96-F84F-462C-B73B-C4B896789AD7Q37146751-3872DD63-DFBD-4AD5-A82C-04FA3B9D2A07Q37172147-580DB35C-5EBE-45D0-A7D3-8AA68785C71CQ37313508-8012B6D0-301E-4F72-971B-5E5F68A90EFCQ37688163-0F780B27-0ED2-4614-82C7-C5D3BC907C34Q38003504-039D190E-5063-4C11-9F71-38590725A379Q41370079-15E15B5E-46A1-45FC-BF50-37A4DB86781CQ43151444-6802593A-6821-4968-B890-2D5FDA8CD58BQ43767305-2678CEFB-901F-4749-AA73-27F759DC4D16Q44306520-2D94B92E-4B6D-4B3C-BE20-BBB03CE5E51FQ46504860-A413E2D2-9615-4F05-9B44-500643A37544
P2860
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@ast
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@en
type
label
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@ast
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@en
prefLabel
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@ast
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@en
P2093
P2860
P50
P356
P1476
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603473
P407
P50
P577
2006-11-21T00:00:00Z